These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
235 related articles for article (PubMed ID: 33644235)
21. Response and Duration of Serum Anti-SARS-CoV-2 Antibodies After Inactivated Vaccination Within 160 Days. Xu QY; Xue JH; Xiao Y; Jia ZJ; Wu MJ; Liu YY; Li WL; Liang XM; Yang TC Front Immunol; 2021; 12():786554. PubMed ID: 35003104 [TBL] [Abstract][Full Text] [Related]
22. Development and characterization of two equine formulations towards SARS-CoV-2 proteins for the potential treatment of COVID-19. León G; Herrera M; Vargas M; Arguedas M; Sánchez A; Segura Á; Gómez A; Solano G; Corrales-Aguilar E; Risner K; Narayanan A; Bailey C; Villalta M; Hernández A; Sánchez A; Cordero D; Solano D; Durán G; Segura E; Cerdas M; Umaña D; Moscoso E; Estrada R; Gutiérrez J; Méndez M; Castillo AC; Sánchez L; Sánchez R; Gutiérrez JM; Díaz C; Alape A Sci Rep; 2021 May; 11(1):9825. PubMed ID: 33972631 [TBL] [Abstract][Full Text] [Related]
23. Evaluation of a SARS-CoV-2 Capture IgM Antibody Assay in Convalescent Sera. Ha B; Jadhao S; Hussaini L; Gibson T; Stephens K; Salazar L; Ciric C; Taylor M; Rouphael N; Edupuganti S; Rostad CA; Tompkins SM; Anderson EJ; Anderson LJ Microbiol Spectr; 2021 Oct; 9(2):e0045821. PubMed ID: 34494855 [TBL] [Abstract][Full Text] [Related]
24. Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies. Barnes CO; West AP; Huey-Tubman KE; Hoffmann MAG; Sharaf NG; Hoffman PR; Koranda N; Gristick HB; Gaebler C; Muecksch F; Lorenzi JCC; Finkin S; Hägglöf T; Hurley A; Millard KG; Weisblum Y; Schmidt F; Hatziioannou T; Bieniasz PD; Caskey M; Robbiani DF; Nussenzweig MC; Bjorkman PJ Cell; 2020 Aug; 182(4):828-842.e16. PubMed ID: 32645326 [TBL] [Abstract][Full Text] [Related]
25. Correlation between Clinical Characteristics and Antibody Levels in COVID-19 Convalescent Plasma Donor Candidates. Uzun G; Müller R; Althaus K; Becker M; Marsall P; Junker D; Nowak-Harnau S; Schneiderhan-Marra N; Klüter H; Schrezenmeier H; Bugert P; Bakchoul T Viruses; 2023 Jun; 15(6):. PubMed ID: 37376656 [TBL] [Abstract][Full Text] [Related]
26. Sex Disparities and Neutralizing-Antibody Durability to SARS-CoV-2 Infection in Convalescent Individuals. Markmann AJ; Giallourou N; Bhowmik DR; Hou YJ; Lerner A; Martinez DR; Premkumar L; Root H; van Duin D; Napravnik S; Graham SD; Guerra Q; Raut R; Petropoulos CJ; Wrin T; Cornaby C; Schmitz J; Kuruc J; Weiss S; Park Y; Baric R; de Silva AM; Margolis DM; Bartelt LA mSphere; 2021 Aug; 6(4):e0027521. PubMed ID: 34431693 [TBL] [Abstract][Full Text] [Related]
27. Declining Levels of Neutralizing Antibodies Against SARS-CoV-2 in Convalescent COVID-19 Patients One Year Post Symptom Onset. Xiang T; Liang B; Fang Y; Lu S; Li S; Wang H; Li H; Yang X; Shen S; Zhu B; Wang B; Wu J; Liu J; Lu M; Yang D; Dittmer U; Trilling M; Deng F; Zheng X Front Immunol; 2021; 12():708523. PubMed ID: 34220870 [TBL] [Abstract][Full Text] [Related]
28. Production of anti-SARS-CoV-2 hyperimmune globulin from convalescent plasma. Vandeberg P; Cruz M; Diez JM; Merritt WK; Santos B; Trukawinski S; Wellhouse A; Jose M; Willis T Transfusion; 2021 Jun; 61(6):1705-1709. PubMed ID: 33715160 [TBL] [Abstract][Full Text] [Related]
29. A non-RBM targeted RBD specific antibody neutralizes SARS-CoV-2 inducing S1 shedding. Long Y; Song S; Luo F; Han X; Hu C; Wang Y; Li S; Wang W; Zhang H; Zhang B; Li T; Jin A Biochem Biophys Res Commun; 2021 Sep; 571():152-158. PubMed ID: 34325131 [TBL] [Abstract][Full Text] [Related]
30. Comparison of Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibodies' Binding Capacity Between Human Milk and Serum from Coronavirus Disease 2019-Recovered Women. Demers-Mathieu V; DaPra C; Medo E Breastfeed Med; 2021 May; 16(5):393-401. PubMed ID: 33835835 [No Abstract] [Full Text] [Related]
31. SARS-CoV-2-specific humoral and cellular immunity in two renal transplants and two hemodialysis patients treated with convalescent plasma. Lindemann M; Krawczyk A; Dolff S; Konik M; Rohn H; Platte M; Thümmler L; Schwarzkopf S; Schipper L; Bormann M; van de Sand L; Breyer M; Klump H; Knop D; Lenz V; Temme C; Dittmer U; Horn PA; Witzke O J Med Virol; 2021 May; 93(5):3047-3054. PubMed ID: 33527424 [TBL] [Abstract][Full Text] [Related]
32. Two Opposing Roles of SARS-CoV-2 RBD-Reactive Antibodies in Pre-Pandemic Plasma Samples From Elderly People in ACE2-Mediated Pseudovirus Infection. Sim KY; Ko GH; Bae SE; Choi KY; Lee JS; Kim BC; Lee KH; Song MR; Park SG Front Immunol; 2021; 12():813240. PubMed ID: 35087532 [TBL] [Abstract][Full Text] [Related]
33. Anti-SARS-CoV-2 IgG and IgA antibodies in COVID-19 convalescent plasma do not enhance viral infection. Clark NM; Janaka SK; Hartman W; Stramer S; Goodhue E; Weiss J; Evans DT; Connor JP PLoS One; 2022; 17(3):e0257930. PubMed ID: 35259162 [TBL] [Abstract][Full Text] [Related]
34. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. Weisblum Y; Schmidt F; Zhang F; DaSilva J; Poston D; Lorenzi JC; Muecksch F; Rutkowska M; Hoffmann HH; Michailidis E; Gaebler C; Agudelo M; Cho A; Wang Z; Gazumyan A; Cipolla M; Luchsinger L; Hillyer CD; Caskey M; Robbiani DF; Rice CM; Nussenzweig MC; Hatziioannou T; Bieniasz PD Elife; 2020 Oct; 9():. PubMed ID: 33112236 [TBL] [Abstract][Full Text] [Related]
35. Neutralization of SARS-CoV-2 with IgG from COVID-19-convalescent plasma. Maeda K; Higashi-Kuwata N; Kinoshita N; Kutsuna S; Tsuchiya K; Hattori SI; Matsuda K; Takamatsu Y; Gatanaga H; Oka S; Sugiyama H; Ohmagari N; Mitsuya H Sci Rep; 2021 Mar; 11(1):5563. PubMed ID: 33692457 [TBL] [Abstract][Full Text] [Related]